导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.34% | 761/4773 |
| 近一周 | -2.91% | 3362/5462 |
| 近一月 | -3.53% | 1814/5421 |
| 近一季 | -4.54% | 1655/5209 |
| 近半年 | 4.96% | 799/4920 |
| 近一年 | 13.53% | 775/4366 |
| 近两年 | 73.10% | 917/2954 |
| 近三年 | 48.90% | 552/2253 |
| 成立以来 | 150.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.39% 2772/4961 |
22.70% 1115/5312 |
- - |
- - |
| 2025 | 31.47% 1235/4813 |
-0.69% 2356/3635 |
5.41% 595/4076 |
21.39% 1804/4524 |
3.46% 670/4813 |
| 2024 | 13.63% 1125/3463 |
1.68% 862/2808 |
-0.49% 771/3014 |
16.87% 1325/3129 |
-3.91% 2403/3463 |
| 2023 | -11.47% 1404/2656 |
1.52% 1554/2280 |
-4.11% 1051/2385 |
-0.94% 469/2515 |
-8.20% 2262/2655 |
| 2022 | -14.85% 396/2207 |
-13.15% 705/1919 |
9.03% 305/2016 |
-14.13% 1028/2113 |
4.73% 513/2208 |
| 2021 | 10.16% 441/1822 |
-1.56% 514/1255 |
8.10% 646/1330 |
-1.93% 549/1466 |
5.56% 284/1822 |
| 2020 | 85.59% 31/1250 |
-3.53% 306/1028 |
32.27% 31/1067 |
23.69% 29/1164 |
17.59% 119/1184 |
| 2019 | 47.27% 124/1092 |
21.99% 584/739 |
0.30% 169/788 |
10.90% 43/850 |
8.53% 307/918 |
| 2018 | - - |
- - |
-12.31% 383/631 |
-5.84% 383/660 |
-16.79% 646/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富荣沪深300指数增强A VS. 长安沪深300非周期A(740101) |